文献速递膀胱癌与上尿路尿路上皮癌

新型尿液生物标志物检测在非肌层浸润性膀胱癌中的诊断准确性:系统评价与网状Meta分析

Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2021-11-06

该系统评价与网状Meta分析检索截至2021年4月的文献,纳入21项研究共7330例患者,评估新型尿液生物标志物检测对非肌层浸润性膀胱癌诊断与监测的诊断价值。结果显示这些检测在监测场景敏感性最高达93%、特异性最高达84%、阴性预测值最高达99%,在1000例患者随访中可能避免多达740次膀胱镜检查,网状Meta分析显示除特异性外诊断价值显著高于细胞学。作者认为数据支持其在监测中的应用,但用于初始诊断的数据不足,需在更大队列及头对头比较研究中确认。

要点

  • 新型尿液生物标志物检测在非肌层浸润性膀胱癌监测中敏感性最高达93%,特异性最高达84%。
  • 随访1000例患者中,这些检测可能避免多达740次膀胱镜检查。
  • 网状Meta分析显示除特异性外,新型检测诊断价值显著高于细胞学。

核心结论

  • 作者认为分析支持所研究新型尿液生物标志物检测具有高诊断准确性,支持其在非肌层浸润性膀胱癌监测场景中的应用。
  • 这些检测可能有助于安全地避免不必要的膀胱镜检查。
  • 用于初始诊断场景的数据不足,无法可靠评估其应用。
  • 结果需在更大队列及头对头比较研究中确认。
  • 研究可能帮助政策制定者和利益相关者评估将这些检测纳入日常实践的临床和社会影响。

研究设计与样本

  • 系统评价与网状Meta分析,检索PubMed、Web of Science和Scopus截至2021年4月的文献。
  • 纳入21项研究,共7330例患者进入定量合成。
  • 主要终点为采用诊断试验准确性Meta分析评估非肌层浸润性膀胱癌患者疾病复发的汇总诊断价值,并用网状Meta分析与细胞学比较。
  • 次要终点为高级别复发的诊断价值以及膀胱癌初始检测的诊断价值。

主要发现

  • 在非肌层浸润性膀胱癌监测中,新型尿液生物标志物检测的汇总敏感性最高达93%,特异性最高达84%,阳性预测值最高达67%,阴性预测值最高达99%。
  • 高级别复发诊断的汇总估计值与任何级别复发诊断的汇总估计值相似。
  • 在1000例患者随访中,分析显示这些检测可能有效减少可避免的干预,最多可避免740次膀胱镜检查。
  • 网状Meta分析显示,除特异性外,新型尿液生物标志物检测对非肌层浸润性膀胱癌复发的诊断价值显著高于细胞学。
  • 初始诊断场景中关于尿液生物标志物检测的数据过少,无法进行统计分析。

关键数值与推荐

  • 非肌层浸润性膀胱癌监测:汇总敏感性最高达93%,特异性最高达84%,阳性预测值最高达67%,阴性预测值最高达99%。
  • 1000例患者随访中可能避免的膀胱镜检查数最多达740次。

临床怎么用

  • 作者认为这些检测的高诊断准确性支持其在非肌层浸润性膀胱癌监测场景中的应用。
  • 作者认为这些检测可能有助于安全地避免不必要的膀胱镜检查。
  • 作者指出初始诊断场景数据不足,无法可靠评估其应用。

局限性

  • 大多数研究存在不明确的偏倚风险。
  • 初始诊断场景中关于尿液生物标志物检测的数据过少,无法进行统计分析。
  • 结果需在更大队列及头对头比较研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: During the past decade, several urinary biomarker tests (UBTs) for bladder cancer have been developed and made commercially available. However, none of these is recommended by international guidelines so far. OBJECTIVE: To assess the diagnostic estimates of novel commercially available UBTs for diagnosis and surveillance of non-muscle-invasive bladder cancer (NMIBC) using diagnostic test accuracy (DTA) and network meta-analysis (NMA). EVIDENCE ACQUISITION: PubMed, Web of Science, and Scopus were searched up to April 2021 to identify studies addressing the diagnostic values of UBTs: Xpert bladder cancer, Adxbladder, Bladder EpiCheck, Uromonitor and Cxbladder Monitor, and Triage and Detect. The primary endpoint was to assess the pooled diagnostic values for disease recurrence in NMIBC patients using a DTA meta-analysis and to compare them with cytology using an NMA. The secondary endpoints were the diagnostic values for high-grade (HG) recurrence as well as for the initial detection of bladder cancer. EVIDENCE SYNTHESIS: Twenty-one studies, comprising 7330 patients, were included in the quantitative synthesis. In most of the studies, there was an unclear risk of bias. For NMIBC surveillance, novel UBTs demonstrated promising pooled diagnostic values with sensitivities up to 93%, specificities up to 84%, positive predictive values up to 67%, and negative predictive value up to 99%. Pooled estimates for the diagnosis of HG recurrence were similar to those for the diagnosis of any-grade recurrence. The analysis of the number of cystoscopies potentially avoided during the follow-up of 1000 patients showed that UBTs might be efficient in reducing the number of avoidable interventions with up to 740 cystoscopies. The NMA revealed that diagnostic values (except specificity) of the novel UBTs were significantly higher than those of cytology for the detection of NMIBC recurrence. There were too little data on UBTs in the primary diagnosis setting to allow a statistical analysis. CONCLUSIONS: Our analyses support high diagnostic accuracy of the studied novel UBTs, supporting their utility in the NMIBC surveillance setting. All of these might potentially help prevent unnecessary cystoscopies safely. There are not enough data to reliably assess their use in the primary diagnostic setting. These results have to be confirmed in a larger cohort as well as in head-to-head comparative studies. Nevertheless, our study might help policymakers and stakeholders evaluate the clinical and social impact of the implementation of these tests into daily practice. PATIENT SUMMARY: Novel urinary biomarker tests outperform cytology with the potential of improving routine clinical practice by preventing unnecessary cystoscopic examinations during the surveillance of non-muscle-invasive bladder cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Laukhtina E, Shim SR, Mori K, et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2021. PMID: 34753702. doi:10.1016/j.euo.2021.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。